Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
San Francisco Chronicle - Wednesday, August 4, 2004
If she misses a few doses or mistakenly takes too many pills, her health may waver.
In the world of AIDS treatment, this woman represents a dilemma. Powerful drugs can hold the infection at bay, but the pills are costly and complicated to take. Clearly, medicine, and the politics behind it, can do better.
This problem may be eased by combining medications into a single cocktail pill and chopping the price. Drug patents and safety worries blocked this goal -- until now.
The Food and Drug Administration approved two combination pills by GlaxoSmithKline and Gilead Sciences this week that simplify treatment. Each pill lets a patient take two AIDS-fighting drugs in a once-a-day tablet.
Perhaps even bigger is an apparent decision by Ranbaxy Laboratories, a major drug firm in India, to submit its generic combination pill to the FDA for approval. Ranbaxy, like many foreign drugmakers, has stamped out cheap copies of U.S. drugs for use in poor countries. It makes a three-in-one combination pill that AIDS-care groups believe holds huge promise.
Until now, the White House's $15 billion AIDS program wouldn't buy foreign generics, which violate drug U.S. patents. So a compromise was struck: If the foreign generics met FDA safety rules, they could be used in poor countries.
Ranbaxy is the first major player to seek FDA approvals, which will be speeded up especially for AIDS generics.
This is more than a dry tale of a balky trade dispute. AIDS may have subsided as a health worry in the United States, but it is a raging epidemic in Africa and Asia. Worldwide, nearly 40 million people are infected, and 3 million died from AIDS-caused disease in 2003.
Though a cure doesn't yet exist, life-prolonging drugs can block the AIDS virus from spreading in the body. This treatment allows adults to hold a job, children to attend school and families to stay together. At present, there are 6 million people who could benefit from anti-AIDS drugs, but only 400,000 receive pills. Providing cheaper combination pills should close this dangerous gap.
040804
SC040803
Copyright © 2004 - San Francisco Chronicle Press. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the San Francisco Chronicle, Permissions Desk, 901 Mission Street, San Franciso, CA 94103. You may also send a fax to (415) 495-3843, or an email message to chronperm@sfgate.com. http://www.sfgate.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .